Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01936909 · ClinicalTrials.gov registry record · Phase 2
Interleukin-1 Blockade in Recently Decompensated Heart Failure
A Phase 2 study of Heart Failure, sponsored by Virginia Commonwealth University.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT01936909 is a Phase 2 study of Heart Failure that has completed, run by Virginia Commonwealth University. The registered enrollment target is 60 participants, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01936909, a Phase 2 study of Heart Failure, has completed, sponsored by Virginia Commonwealth University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
The RED-HART is a randomized double-blinded placebo-controlled study of Anakinra (IL-1 blocker) in patients with recently decompensated heart failure to determine the safety and efficacy in terms of aerobic exercise capacity and ventilatory efficiency measured with a cardiopulmonary exercise test.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Anakinra (weeks 1-2)
- DRUG Anakinra (weeks 3-12)
Study Locations (1)
Virginia
- Virginia Commonwealth University - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2014-02 |
| Est. Completion | 2016-09-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01936909
The ClinicalTrials.gov registry entry for NCT01936909 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (97% lower). The listed sponsor is Virginia Commonwealth University, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Heart Failure appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT01936909 reports 1 study location spanning 1 distinct geographic area - top geographies include Virginia.
Frequently Asked Questions
What is clinical trial NCT01936909 about?
NCT01936909 is a clinical study titled "Interleukin-1 Blockade in Recently Decompensated Heart Failure". The RED-HART is a randomized double-blinded placebo-controlled study of Anakinra (IL-1 blocker) in patients with recently decompensated heart failure to determine the safety and efficacy in terms of aerobic exercise capacity and ventilatory efficiency measured with a cardiopulmonary exercise test.
What is the current status of trial NCT01936909?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2014-02. Estimated completion is 2016-09-23.
What conditions does trial NCT01936909 study?
This clinical trial studies the following conditions: Heart Failure.
What interventions are being tested in trial NCT01936909?
The interventions under investigation include: Placebo (DRUG), Anakinra (weeks 1-2) (DRUG), Anakinra (weeks 3-12) (DRUG).
Who is sponsoring clinical trial NCT01936909?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01936909 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF)
RECRUITING · Phase 2
-
Improving Cardiac Rehabilitation Exercise Using Target Heart Rate Trial
RECRUITING · Phase 2
-
Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)
RECRUITING · Phase 2
-
Multicenter Trial of ECMO in Children With Severe Cardiac Failure Using the Cardiohelp System
RECRUITING · Phase 2
-
Metformin for Pulmonary Hypertension HFpEF
RECRUITING · Phase 2
-
The Inorganic Nitrate and eXercise Performance in Heart Failure (iNIX-HF)
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.